TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03921593

Intervention type: PROCEDURE
Intervention: Solid Organ Pancreas Transplantation with or without Kidney Transplantation
Description: Deceased donor pancreas transplantation

Intervention type: PROCEDURE
Intervention: Solid Organ Pancreas Transplantation with or without Kidney Transplantation
Description: Deceased donor pancreas transplantation

Intervention type: PROCEDURE
Intervention: Solid Organ Pancreas Transplantation with or without Kidney Transplantation
Description: Deceased donor pancreas transplantation
Study: NCT03503786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
Study: NCT04057079

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anugel, Hydrogel sponge
Description: A calibrated sponge impregnated with hydrogel is inserted to the rectum post hemoroidectomy.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Gelatine Sponge
Description: A gelatine sponge is inserted in to the rectum pos hemoroidectomy.
Study: NCT00511615

Intervention type: PROCEDURE
Intervention: Loop Electrosurgical Excision Procedure (LEEP)
Description: Tissue sample removed from cervix using LEEP and contrast agent.
Study: NCT04592029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with sintilimab and bevacizumab
Description: Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg/kg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.
Study: NCT00584142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
Study: NCT04025658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin administered intravenously, over 1 minute following delivery of the fetal head

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin administered intravenously, over 1 minute following delivery of the fetal head

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin administered intravenously, over 1 minute following delivery of the fetal head

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin administered intravenously, over 1 minute following delivery of the fetal head

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin administered intravenously, over 1 minute following delivery of the fetal head

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
Study: NCT01999335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets for oral administration
Study: NCT03420989

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active snack food
Description: snack enriched with seaweeds and carob

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control snack food
Description: the same snack food without seaweeds and carob
Study: NCT00557362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natamycin 5%
Description: One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natamycin 5%
Description: One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal de-epithelialization
Description: Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal de-epithelialization
Description: Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
Study: NCT00801047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 40-50 mic per 1-2 min via PCA
Study: NCT02839239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drops with lactobacilli and vitamin D3
Description: Oil suspension with lactobacilli and vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Drops with vitamin D3
Description: Oil suspension with vitamin D3
Study: NCT03453840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.
Study: NCT03664947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: After the initial evaluations, a video-based gaming console exercise program will be implemented for 8 weeks, taking into account the possibility of accepting and participating in treatment with children. Exercises applied by a Nintendo Wii Fit Plus System. Evaluations will be repeated at the end of treatment.
Study: NCT02492620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Citrate
Description: Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
Study: NCT01694979

Intervention type: OTHER
Intervention: Minimum expiration effort
Description: Subjects perform a forced expiration at minimum effort

Intervention type: OTHER
Intervention: Moderate expiration effort
Description: Subjects perform a forced expiration at moderate effort

Intervention type: OTHER
Intervention: Maximum expiration effort
Description: Subjects perform a forced expiration at maximum effort
Study: NCT02786680

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stroop test in condition DBS off
Description: Patients were evaluated in DBS Off

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stroop test in condition DBS on
Description: Patients were evaluated in DBS On
Study: NCT00444977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case-management linkage intervention
Description: dental care
Study: NCT00262990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 (Patupilone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Study: NCT04108728

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BRIEF SCORE AT INCLUSION
Description: BRIEF SCALE evaluation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: BRIEF SCORE AT INCLUSION
Description: BRIEF SCALE evaluation
Study: NCT02699372

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01999335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets for oral administration
Study: NCT02699372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889450
Study: NCT01124045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate ophthalmic emulsion, 0.05%
Description: Topical ocular administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate ophthalmic suspension, 1.0%
Description: Topical ocular administration
Study: NCT00730249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate hydrochloride
Description: sustained release, twice daily, dosage according to an individual titration schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily according to an individual titration schedule
Study: NCT02411292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
Study: NCT02149927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study: NCT04308057

Intervention type: PROCEDURE
Intervention: Aquatic exercise
Description: Participants belonging to Group D (sedentary group) will be randomised 1-to-1 between remaining sedentary (n=20) and following a self-managed, 8-week, aquatic-based exercise programme (n=20). The latter group will be offered an 8-week access to pool facilities. For Group D participants, all baseline assessments will be repeated at 8 weeks.
Study: NCT03629821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballet
Description: The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
Study: NCT01010906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg
Description: single dose administration of 300 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg
Description: single dose administration of 300 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg
Description: single dose administration of 300 mg oral tablet
Study: NCT03800771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycléo BRAU
Description: Practice dual-task tests.
Study: NCT01577927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual home care
Description: Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PT-assisted home rehabilitation
Description: Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement.
Study: NCT03800771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAITRITE®
Description: Routine practice dual-task tests.
Study: NCT05640258

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: rotatory chair testing in a velocity step protocol.
Description: Tc was evaluated by the rotational velocity step test using the OtoaccessTM interface (Interacoustics Nydiag 200, Middlefart, Denmark). Subjects were seated on the rotatory chair wearing videonystagmography goggles with their heads supported and tilted 30° forward, thus bringing the horizontal semicircular canals plane perpendicular to the axis of rotation. Standard videonystagmography techniques were employed to record eye-movements. Subsequent to eye movements' calibration, the chair was accelerated about the yaw axis at 30°/sec2 to a maximal velocity of 90°/sec, followed by rotation at a constant velocity. After 57 seconds of constant velocity rotation, the chair was decelerated to zero velocity at 30°/sec2. The described velocity step was conducted both clockwise and counter-clockwise, giving a total run time of 4 minutes.
Study: NCT01402622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol anesthesia
Description: In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol anesthesia
Description: In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol anesthesia
Description: In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
Study: NCT03732040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: miswak stick
Description: miswak stick use as preventive hygiene measures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miswak plus tooth brushing and tooth paste
Description: use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)
Description: use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
Study: NCT00611351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT01802242

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy
Description: Patients in this group will receive one of 2 treatment arms of their choice:~* Arm 1: VMAT delivery with integrated VMAT boost (IB-VMAT) GTV: 95Gy in 38fractions~* Arm 2: HDR-boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT

Intervention type: OTHER
Group type: OTHER
Intervention: No Active Treatment - completed Prior Radiation
Description: Already had prior radiation treatment. MRI-guided prostate biopsy at 3 years and PSA per standard practice
Study: NCT01010906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg
Description: single dose administration of 300 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 200 mg
Description: single dose administration of 200 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 200 mg
Description: single dose administration of 200 mg oral tablet
Study: NCT03928847

Intervention type: DRUG
Group type: OTHER
Intervention: Epigallocatechin-3-gallate (EGCG)
Description: Epigallocatechin-3-gallate (EGCG) capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Epigallocatechin-3-gallate (EGCG)
Description: Epigallocatechin-3-gallate (EGCG) capsules
Study: NCT03973827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProTrans
Description: Single infusion of 25, 100 or 200 million cells per patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProTrans
Description: Single infusion of 25, 100 or 200 million cells per patient.
Study: NCT02173288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Study: NCT01488084

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Graft Surgery
Description: Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Graft Surgery
Description: Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional open SVG harvesting
Description: SVG harvested using conventional open technique and manually distended with crystalloid solution
Study: NCT03132636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Regimen as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Regimen as per protocol
Study: NCT03973827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProTrans
Description: Single infusion of 25, 100 or 200 million cells per patient.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Sham transplantation (placebo) Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)